Pharmacogenomic Analyses Implicate B Cell Developmental Status and <i>MKL1</i> as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

Pharmacogenomic Analyses Implicate B Cell Developmental Status and <i>MKL1</i> as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

Monoclonal antibody (mAb) therapy directed against CD20 is an important tool in the treatment of B cell disorders. However, variable patient response and acquired resistance remain important clinical challenges. To identify genetic factors that may influence sensitivity to treatment, the cytotoxic a...

Full description

Bibliographic Details
Main Authors: George W. Small, Farida S. Akhtari, Adrian J. Green, Tammy M. Havener, Michael Sikes, Julia Quintanhila, Ricardo D. Gonzalez, David M. Reif, Alison A. Motsinger-Reif, Howard L. McLeod, Tim Wiltshire
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cells
Subjects:
rituximab (Rituxan<sup>®</sup>)
ofatumumab (Arzerra<sup>®</sup>, Kesimpta<sup>®</sup>)
obinutuzumab (Gazyva<sup>®</sup>)
CD20 (<i>MS4A1</i>)
<i>MKL1</i> (<i>MRTFA</i>)
<i>TGFB1</i>
Online Access:https://www.mdpi.com/2073-4409/12/12/1574

Internet

https://www.mdpi.com/2073-4409/12/12/1574

Similar Items